Database : MEDLINE
Search on : Stupor [Words]
References found : 10103 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1011 go to page                         

  1 / 10103 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29521882
[Au] Autor:Funayama M; Takata T; Koreki A; Ogino S; Mimura M
[Ti] Title:Catatonic Stupor in Schizophrenic Disorders and Subsequent Medical Complications and Mortality.
[So] Source:Psychosom Med;, 2018 Mar 08.
[Is] ISSN:1534-7796
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Although catatonia can occur secondary to a general medical condition, catatonia itself has been known to lead to various medical compolications. Although case reports on the association of catatonia with subsequent medical complications have been documented, no comprehensive large-scale study has been performed. To investigate specific medical complications following catatonia, we conducted a retrospective cohort study of specific medical complications of schizophrenia patients with catatonia. METHODS: The 1719 schizophrenia inpatients in our study were categorized into two groups: the catatonia group, i.e., those who exhibited catatonic stupor while they were hospitalized, and the non-catatonia group, which were those who never exhibited catatonic stupor. 'Differences between the two groups in the occurrence of subsequent medical complications were examined using linear and logistic regression analyses, and models were adjusted for potentially confounding factors.' RESULTS: The catatonia group had an increased risk for mortality (OR=4.8, 95% CI 2.0 to 10.6, P<0.01) and certain specific medical complications, i.e., pneumonia, urinary tract infection, sepsis, disseminated intravascular coagulation, rhabdomyolysis, dehydration, deep venous thrombosis, pulmonary embolism, urinary retention, decubitus, arrhythmia, renal failure, neuroleptic malignant syndrome, hypernatremia, and liver dysfunction (all P < 0.01, except for deep venous thrombosis, P =0.04) in the multiple linear regression analysis). CONCLUSIONS: Catatonic stupor in schizophrenia substantially raises the risk for specific medical complications and mortality. Hyperactivity of the sympathetic nervous system, dehydration, and immobility, which are frequently involved in catatonia, might contribute to these specific medical complications. In catatonia, meticulous care for both mental and medical conditions should be taken to reduce the risk of adverse medical consequences.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1097/PSY.0000000000000574

  2 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29468621
[Au] Autor:Chen YJ; Chou CL; Lai KJ; Lin YL
[Ad] Address:Department of Neurology, MacKay Memorial Hospital, Taipei, Taiwan.
[Ti] Title:Fusarium Brain Abscess in a Patient with Diabetes Mellitus and Liver Cirrhosis.
[So] Source:Acta Neurol Taiwan;26(3):128-132, 2017 Sep 15.
[Is] ISSN:1028-768X
[Cp] Country of publication:China (Republic : 1949- )
[La] Language:eng
[Ab] Abstract:PURPOSE: Invasive mycosis caused by the Aspergillus, Fusarium, and Mucor can be fetal, especially in the immunocompromised patients with central nervous system (CNS) involvement. Here we present a case of CNS Fusarium infection, and this is the first reported case of Fusarium brain abscess in Taiwan. CASE REPORT: A 65-year-old woman presented with fever and conscious disturbance for 3 days. Neurological examination showed stupor consciousness, neck stiffness, multiple cranial nerves palsy, and bilateral Babinski signs. Magnetic resonance imaging showed multifocal lesions involving medulla oblongata, pons, bilateral cerebral peduncles, and bilateral cerebellar peduncles. Cerebrospinal fluid (CSF) study revealed neutrophil predominant pleocytosis, but both blood and CSF culture were negative. We treated patient with ceftriaxone and vancomycin initially as empiric therapy for suspected bacterial meningoencephalitis. However, chronic sinusitis with fungal ball and brain abscess were later found. Despite antifungal treatment and surgical intervention, patient expired 3 months after admission. Fungal culture of the brain abscess disclosed Fusarium species 2 weeks after her death. CONCLUSION: CNS Fusarium infection should be considered when an immunocompromised patient presenting with fever, conscious change, cranial nerve palsies, and angioinvasion suggested by brain imaging. To properly manage the disease, early effective antifungal therapy and neurosurgical intervention are important.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Data-Review

  3 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29329548
[Au] Autor:Howard SW; Zhang Z; Buchanan P; Bernell SL; Williams C; Pearson L; Huetsch M; Gill J; Pineda JA
[Ad] Address:Saint Louis University, Health Management and Policy, Salus Center 374, 3545 Lafayette Ave., St. Louis, MO, 63104, USA. Steven.Howard@SLU.edu.
[Ti] Title:The cost of a pediatric neurocritical care program for traumatic brain injury: a retrospective cohort study.
[So] Source:BMC Health Serv Res;18(1):20, 2018 01 12.
[Is] ISSN:1472-6963
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Inpatient care for children with severe traumatic brain injury (sTBI) is expensive, with inpatient charges averaging over $70,000 per case (Hospital Inpatient, Children Only, National Statistics. Diagnoses- clinical classification software (CCS) principal diagnosis category 85 coma, stupor, and brain damage, and 233 intracranial injury. Diagnoses by Aggregate charges [ https://hcupnet.ahrq.gov/#setup ]). This ranks sTBI in the top quartile of pediatric conditions with the greatest inpatient costs (Hospital Inpatient, Children Only, National Statistics. Diagnoses- clinical classification software (CCS) principal diagnosis category 85 coma, stupor, and brain damage, and 233 intracranial injury. Diagnoses by Aggregate charges [ https://hcupnet.ahrq.gov/#setup ]). The Brain Trauma Foundation developed sTBI intensive care guidelines in 2003, with revisions in 2012 (Kochanek, Carney, et. al. PCCM 3:S1-S2, 2012). These guidelines have been widely disseminated, and are associated with improved health outcomes (Pineda, Leonard. et. al. LN 12:45-52, 2013), yet research on the cost of associated hospital care is limited. The objective of this study was to assess the costs of providing hospital care to sTBI patients through a guideline-based Pediatric Neurocritical Care Program (PNCP) implemented at St. Louis Children's Hospital, a pediatric academic medical center in the Midwest United States. METHODS: This is a retrospective cohort study. We used multi-level regression to estimate pre-/post-implementation effects of the PNCP program on inflation adjusted total cost of in-hospital sTBI care. The study population included 58 pediatric patient discharges in the pre-PNCP implementation group (July 15, 1999 - September 17, 2005), and 59 post-implementation patient discharges (September 18, 2005 - January 15, 2012). RESULTS: Implementation of the PNCP was associated with a non-significant difference in the cost of care between the pre- and post-implementation periods (e = 1.028, p = 0.687). CONCLUSIONS: Implementation of the PNCP to support delivery of guideline-based care for children with sTBI did not change the total per-patient cost of in-hospital care. A key strength of this study was its use of hospital cost data rather than charges. Future research should consider the longitudinal post-hospitalization costs of this approach to sTBI care.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1801
[Cu] Class update date: 180217
[Lr] Last revision date:180217
[St] Status:In-Process
[do] DOI:10.1186/s12913-017-2768-0

  4 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Lopes, Marcos Venícios de Oliveira
SciELO Brazil full text

[PMID]: 29412294
[Au] Autor:Aquino WKM; Lopes MVO; Silva VMD; Fróes NBM; Menezes AP; Almeida AAP; Sobreira BA
[Ad] Address:Universidade Federal do Ceará, Postgraduate Program in Nursing. Fortaleza, Ceará, Brazil.
[Ti] Title:Accuracy of the defining characteristics in nursing diagnoses of Hyperthermia in newborns.
[So] Source:Rev Bras Enferm;71(2):357-362, 2018 Mar-Apr.
[Is] ISSN:0034-7167
[Cp] Country of publication:Brazil
[La] Language:eng; por
[Ab] Abstract:OBJECTIVE: to clinically validate the accuracy of the defining characteristics in nursing diagnoses of Hyperthermia in newborns. METHOD: a cross-sectional study conducted in units of medium and high risk in a maternity from the city of Fortaleza-CE. A total of 216 newborns were evaluated to identify the defining characteristics of diagnoses. A latent class model with random effects was used to measure sensitivity and specificity. RESULTS: Hyperthermia was present in 5.6% of the sample. The characteristics lack of suction maintenance (31.3%); skin warm to touch (25.5%); lethargy (24.2%); and tachypnea (21.4%) were the most frequent. Stupor presented higher sensitivity (99.9%) and specificity (100%) while vasodilation characteristics, irritability and lethargy only showed significant values for specificity (92.7%, 91.6% and 74.3%, respectively). CONCLUSION: four characteristics of high specificity contribute to Hyperthemia. However, stupor is the only one with significant sensitivity to identify it at its early-stage.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180207
[Lr] Last revision date:180207
[St] Status:In-Process

  5 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29216295
[Au] Autor:Park J; Masaki T; Mezaki Y; Yokoyama H; Nakamura M; Maehashi H; Fujimi TJ; Gouraud SS; Nagatsuma K; Nakagomi M; Kimura N; Matsuura T
[Ad] Address:Department of Laboratory Medicine, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
[Ti] Title:Alpha-1 antichymotrypsin is involved in astrocyte injury in concert with arginine-vasopressin during the development of acute hepatic encephalopathy.
[So] Source:PLoS One;12(12):e0189346, 2017.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND AND AIMS: We developed a bio-artificial liver (BAL) using a radial-flow bioreactor and rescued mini-pig models with lethal acute liver failure (ALF). The point of the rescue is the recovery from hepatic encephalopathy (HE). HE on ALF has sometimes resulted in brain death following brain edema with astrocyte swelling. Several factors, including ammonia and glutamine, have been reported to induce astrocyte swelling and injury. However, many clinicians believe that there are any other factors involved in the development of HE. Therefore, the aim of this study was to identify novel HE-inducible factors, particularly those inducing astrocyte dysfunction. METHODS: Mini-pig plasma samples were collected at three time points: before the administration of toxins (α-amanitin and LPS), when HE occurred after the administration of toxins, and after treatment with extracorporeal circulation (EC) by the BAL. To identify the causative factors of HE, each plasma sample was subjected to a comparative proteome analysis with two-dimensional gel electrophoresis and mass spectrometry. To assess the direct effects of candidate factors on the astrocyte function and injury, in vitro experiments with human astrocytes were performed. RESULTS: Using a proteome analysis, we identified alpha-1 antichymotrypsin (ACT), which was increased in plasma samples from mini-pigs with HE and decreased in those after treatment with EC by BAL. In in vitro experiments with human astrocytes, ACT showed growth-inhibitory and cytotoxic effects on astrocytes. In addition, the expression of water channel protein aquaporin-4, which is induced in injured astrocytes, was increased following ACT treatment. Interestingly, these effects of ACT were additively enhanced by adding arginine-vasopressin (AVP) and were canceled by adding an AVP receptor antagonist. CONCLUSIONS: These results suggest that ACT is involved in astrocyte injury and dysfunction in concert with AVP during the development of acute HE.
[Mh] MeSH terms primary: Arginine Vasopressin/metabolism
Astrocytes/metabolism
Hepatic Encephalopathy/metabolism
alpha 1-Antichymotrypsin/pharmacology
[Mh] MeSH terms secundary: Acute Disease
Ammonium Chloride/pharmacology
Animals
Astrocytes/drug effects
Cell Line
Hepatic Encephalopathy/pathology
Humans
Liver, Artificial
Male
Swine
Swine, Miniature
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (alpha 1-Antichymotrypsin); 01Q9PC255D (Ammonium Chloride); 113-79-1 (Arginine Vasopressin)
[Em] Entry month:1801
[Cu] Class update date: 180122
[Lr] Last revision date:180122
[Js] Journal subset:IM
[Da] Date of entry for processing:171208
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189346

  6 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Full text

[PMID]: 27775818
[Au] Autor:Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group
[Ad] Address:Gastro Unit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark.
[Ti] Title:Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
[So] Source:Hepatology;65(2):592-603, 2017 02.
[Is] ISSN:1527-3350
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Decompensated cirrhosis is characterized by disturbed systemic and splanchnic hemodynamics. Bacterial translocation from the gut is considered the key driver in this process. Intestinal decontamination with rifaximin may improve hemodynamics. This double-blind, randomized, controlled trial (clinicaltrials.gov, NCT01769040) investigates the effects of rifaximin on hemodynamics, renal function, and vasoactive hormones. We randomized 54 stable outpatients with cirrhosis and ascites to rifaximin 550 mg twice a day (n = 36) or placebo twice a day (n = 18). Forty-five patients were male, mean age 56 years (±8.4), average Child score 8.3 (±1.3), and Model for End-Stage Liver Disease score 11.7 (±3.9). Measurements of hepatic venous pressure gradient, cardiac output, and systemic vascular resistance were made at baseline and after 4 weeks. The glomerular filtration rate and plasma renin, noradrenaline, lipopolysaccharide binding protein, troponin T, and brain natriuretic peptide levels were measured. Rifaximin had no effect on hepatic venous pressure gradient, mean 16.8 ± 3.8 mm Hg at baseline versus 16.6 ± 5.3 mm Hg at follow-up, compared to the placebo, mean 16.4 ± 4 mm Hg at baseline versus 16.3 ± 4.4 mm Hg at follow-up, P = 0.94. No effect was found on cardiac output, mean 6.9 ± 1.7 L/min at baseline versus 6.9 ± 2.3 L/min at follow-up, compared to placebo, mean 6.6 ± 1.9 L/min at baseline compared to 6.5 ±2.1 L/min at follow-up, P = 0.66. No effects on the glomerular filtration rate, P = 0.14, or vasoactive hormones were found. Subgroup analyses on patients with increased lipopolysaccharide binding protein and systemic vascular resistance below the mean (1,011 dynes × s/cm ) revealed no effect of rifaximin. CONCLUSION: Four weeks of treatment with rifaximin did not reduce the hepatic venous pressure gradient or improve systemic hemodynamics in patients with cirrhosis and ascites; rifaximin did not affect glomerular filtration rate or levels of vasoactive hormones. (Hepatology 2017;65:592-603).
[Mh] MeSH terms primary: Gastrointestinal Agents/therapeutic use
Hemodynamics/drug effects
Hepatic Encephalopathy/drug therapy
Liver Cirrhosis/drug therapy
Rifamycins/therapeutic use
[Mh] MeSH terms secundary: Adult
Aged
Denmark
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Glomerular Filtration Rate/drug effects
Hepatic Encephalopathy/etiology
Hepatic Encephalopathy/physiopathology
Hospitals, University
Humans
Hypertension, Portal/prevention & control
Liver Cirrhosis/complications
Liver Cirrhosis/diagnosis
Male
Middle Aged
Outcome Assessment (Health Care)
Patient Selection
Risk Assessment
Severity of Illness Index
Vascular Resistance/drug effects
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Gastrointestinal Agents); 0 (Rifamycins); L36O5T016N (rifaximin)
[Em] Entry month:1708
[Cu] Class update date: 180121
[Lr] Last revision date:180121
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1002/hep.28898

  7 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29187686
[Au] Autor:Matsuda M; Takesako S; Nakazaki M; Nandate T; Umehara F
[Ad] Address:Department of Neurology, Nanpuh Hospital.
[Ti] Title:[Portal-systemic encephalopathy with bilateral thalamic and internal capsule lesions using diffusion-weighted MRI in a super-aged patient].
[So] Source:Rinsho Shinkeigaku;57(12):759-763, 2017 Dec 27.
[Is] ISSN:1882-0654
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:We describe the case of a 90-year-old woman who was hospitalized in July 2016 and subsequently experienced a sudden decline in consciousness level resulting in a state of deep coma. Involuntary movements were not observed, and bilateral Babinski signs were inconclusive. Diffusion-weighted MRI (DWI) of the brain showed bilateral hyperintensity in the thalamus and internal capsule, laboratory testing detected high levels of plasma ammonia, and an electroencephalogram showed delta waves and triphasic waves predominantly in the frontal lobe. Based on these results, treatment for hepatic encephalopathy was administered, which led to an improvement in consciousness level, a decrease in plasma ammonia levels, and a normalization in the DWI scan. Abdominal computed tomography scan showed no abnormality in the liver, but revealed an abnormal blood vessel leading from the ileocolic vein to the inferior vena cava; the patient was diagnosed with portal-systemic encephalopathy. In deep coma patients, acute encephalopathy with hyperammonemia is important for differential diagnosis when DWI shows high-density legions in the thalamus and internal capsule.
[Mh] MeSH terms primary: Diffusion Magnetic Resonance Imaging
Hepatic Encephalopathy/diagnostic imaging
Internal Capsule/diagnostic imaging
Thalamus/diagnostic imaging
[Mh] MeSH terms secundary: Aged, 80 and over
Diagnosis, Differential
Electroencephalography
Female
Hepatic Encephalopathy/complications
Humans
Hyperammonemia/etiology
Tomography, X-Ray Computed
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180112
[Lr] Last revision date:180112
[Js] Journal subset:IM
[Da] Date of entry for processing:171201
[St] Status:MEDLINE
[do] DOI:10.5692/clinicalneurol.cn-001068

  8 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29297141
[Au] Autor:Wijdicks EFM
[Ad] Address:Division of Critical Care Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. wijde@mayo.edu.
[Ti] Title:Lactulose: A Simple Sugar in a Complex Encephalopathy.
[So] Source:Neurocrit Care;, 2018 Jan 02.
[Is] ISSN:1556-0961
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Hepatic encephalopathy is a common encephalopathy and one of the very few that are treatable. Lactulose has remained a standard pharmaceutical intervention and is listed as one of the World Health Organization's Essential Medicines. The discovery of lactulose, the acid dialysis proof of concept, and the role of Bircher are not well known. This historical vignette reviews the gradual understanding of the complex liver-brain connection, the effective treatment of hepatic stupor with lactulose, and the immediate relevance of lactulose to the practice of consultative neurocritical care.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180103
[Lr] Last revision date:180103
[St] Status:Publisher
[do] DOI:10.1007/s12028-017-0494-4

  9 / 10103 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27772635
[Au] Autor:Pena-Polanco JE; Rondon-Berrios H
[Ad] Address:Renal-Electrolyte Division, University of Pittsburgh School of Medicine, Pittsburgh, PA.
[Ti] Title:Quiz Page November 2016: Kidney and Neurologic Complications in the Treatment of a Patient With Hepatic Encephalopathy.
[So] Source:Am J Kidney Dis;68(5):A15-A17, 2016 Nov.
[Is] ISSN:1523-6838
[Cp] Country of publication:United States
[La] Language:eng
[Mh] MeSH terms primary: Acute Kidney Injury/etiology
Alcohol Withdrawal Delirium/complications
Diarrhea/chemically induced
Gastrointestinal Agents/adverse effects
Hepatic Encephalopathy/drug therapy
Hypernatremia/etiology
Lactulose/adverse effects
Myelinolysis, Central Pontine/etiology
Quadriplegia/etiology
[Mh] MeSH terms secundary: Adult
Brain/diagnostic imaging
Diarrhea/complications
Fluid Therapy
Hepatic Encephalopathy/complications
Humans
Hypernatremia/therapy
Magnetic Resonance Imaging
Male
Myelinolysis, Central Pontine/therapy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Gastrointestinal Agents); 4618-18-2 (Lactulose)
[Em] Entry month:1712
[Cu] Class update date: 171205
[Lr] Last revision date:171205
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE

  10 / 10103 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 27777214
[Au] Autor:Hu P; Chen SL; Lin ZP; Zhao JB; Chen Y; He XF; Zeng QL; Li YH
[Ad] Address:Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. E-mail: 740371580@qq.com.
[Ti] Title:[Effect of covered stent length in portal and hepatic veins on long-term clinical efficacy of transjugular intrahepatic portosystemic shunt].
[So] Source:Nan Fang Yi Ke Da Xue Xue Bao;36(10):1444-1448, 2016 Oct 20.
[Is] ISSN:1673-4254
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:OBJECTIVE: To evaluate the effect of the length of covered stents in the portal and hepatic veins on long-term clinical efficacy of transjugular intrahepatic portosystemic shunt (TIPS). METHODS: We retrospectively reviewed 53 cases receiving TIPSs between January, 2008 and December, 2011. All the shunts were created with Fluency stents (8 mm in diameter). Bare metal grafts of the same diameter were implanted to extend the length in the portal and hepatic veins as deemed necessary according to angiographic images. The primary patency, hepatic encephalopathy and patient survival were evaluated during the follow up. The length of the covered stents within the hepatic vein (X1) and in the portal vein (X2), and the total length of stents placed in the hepatic vein (X3) and the portal vein (X4) were measured and their effects on primary patency and the patients'outcomes were evaluated. RESULTS: The procedures were completed successfully in all the patients and the mean portosystemic pressure decreased from 29.80∓4.83 mmHg to 19.00∓3.92 mmHg (t=13.44, P<0.01) after the procedure. The patients were followed up for a median of 64 months (3 to 89 months, 39 months on average). Hepatic encephalopathy occurred in 23% (12/53) of the patients after TIPS. Shunt dysfunction occurred in 16 cases, and the cumulative primary patency rates at 1 to 5 years were 83%, 75%, 63%, 62%, and 54%, respectively. The cumulative survival rates of the patients at 1 to 5 years were 79%, 72%, 72%, 69%, and 69%, respectively. Cox proportional regression analysis showed a significant association between the length of covered-stent in the hepatic vein and the primary patency (OR=0.42, P<0.01), and there was a significant association between the length of stent in the portal vein and the patient survival. No significant correlation was found between these parameters and hepatic encephalopathy. CONCLUSION: Increasing the length of the covered stent in the hepatic vein and decreasing the stent length in the portal vein can improve the primary patency and the patient survival receiving TIPS.
[Mh] MeSH terms primary: Hepatic Veins/surgery
Portal Vein/surgery
Portasystemic Shunt, Transjugular Intrahepatic
Stents
[Mh] MeSH terms secundary: Angiography
Hepatic Encephalopathy
Humans
Retrospective Studies
Survival Rate
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171128
[Lr] Last revision date:171128
[Js] Journal subset:IM
[Da] Date of entry for processing:161026
[St] Status:MEDLINE


page 1 of 1011 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information